KRAS突变晚期非小细胞肺癌诊疗专家共识(2026版)OA
Expert consensus on the diagnosis and treatment of advanced KRAS-mutant non-small cell lung cancer(2026 Edition)
Kirsten大鼠肉瘤病毒癌基因同源物(Kirsten rat sarcoma viral oncogene homolog,KRAS)是非小细胞肺癌(non-small cell lung cancer,NSCLC)关键的驱动基因之一,其激活突变主要发生在第12、13和61位密码子,其中KRASG12C是最常见的突变亚型.KRASG12C突变可驱动肿瘤细胞增殖、侵袭和转移,通常与不良预后及对传统表皮生长因子受体酪氨酸激酶抑制剂的原发性耐药以及对免疫检查点抑制剂疗效的潜在异质性相关,部分亚型呈现"冷肿瘤"免疫微环境特征.近年来,针对KRASG12C突变的共价不可逆抑制剂的相关研究取得了突破性进展.该药能选择性、共价地结合并锁定KRASG12C蛋白,为晚期NSCLC患者带来了靶向治疗选择,显著改善了该类患者的客观缓解率和无进展生存期.为规范我国KRAS突变NSCLC的临床诊疗路径,推动分子检测标准化与创新治疗策略的合理应用,中国抗癌协会肿瘤标志专业委员会、中国抗癌协会整合肿瘤学分会、陕西省抗癌协会纳米肿瘤学专业委员会整合了国内外最新循证医学证据与本土临床实践经验,制定《KRAS突变晚期非小细胞肺癌诊疗专家共识(2026 版)》.共识的最终目标是为KRAS突变NSCLC诊疗的规范化与个体化提供指导,从而改善患者的临床获益,提升其长期生存质量.
Kirsten rat sarcoma viral oncogene homolog(KRAS)is recognized as one of the key driver genes in non-small cell lung cancer,with its activating mutations being primarily observed at codons 12,13,and 61.Among these,KRASG12C is the most common subtype.KRAS mutations,especially the G12C mutation,can drive tumor cell proliferation,invasion,and metastasis.They are frequently associated with poor prognosis,primary resistance to traditional EGFR TKIs,and potential heterogeneity in the efficacy of immune checkpoint inhibitors(ICIs),with some subtypes characterized by a"cold tumor"immune microenvironment.In recent years,breakthroughs have been made in the development of covalent irreversible inhibitors targeting KRASG12C mutations.These drugs selectively and covalently bind and lock the KRASG12C protein,thereby providing targeted therapy options for patients with advanced NSCLC and leading to significantly improved objective response rates and progression-free survival.In order to standardize the clinical diagnosis and treatment pathway of KRAS-mutant NSCLC in China and promote the standardization of molecular testing and the rational application of innovative treatment strategies,Tumor marker professional committee of China anti-cancer association,Integrated oncology branch of the China anti-cancer association,Nanomedicine oncology professional committee of Shaanxi anti-cancer association integrated the latest evidence from evidence-based medicine domestically and internationally with local clinical practice experience and developed the Expert consensus on the diagnosis and treatment of advanced KRAS-mutantnon-small cell lung cancer(2026 Edition).The ultimate goal of the consensus is to provide guidance for the standardized and individualized diagnosis and treatment of KRAS-mutant NSCLC,thereby improving clinical benefit and long-term quality of life for patients.
中国抗癌协会肿瘤标志专业委员会;中国抗癌协会整合肿瘤学分会;陕西省抗癌协会纳米肿瘤学专业委员会;赵征
陕西省肿瘤医院
医药卫生
非小细胞肺癌KRAS突变KRASG12C突变抗肿瘤治疗分子检测随访
Non-small cell lung cancerKRAS mutationKRASG12C mutationAntitumor therapyMolecular detectionFollow-up
《中国癌症防治杂志》 2026 (4)
389-402,14
西安市科技计划重点产业链技术攻关集群项目(24LRHZDZX0023)西安市科技计划医学研究一般项目(24YXYJ0133)
评论